It's true. I know it's easy to cry market manipulation, but this stock seems prone to unusually large smackdowns for no obvious reason. I think there are too many uncommitted shareholders who like to play games. 44 million sellers at 0.8 cents just doesn't make sense given the GBA announcement and that the stock was 1.5 cents prior to that.
Positives: Approved product Sales increasing (from low base) GBA expected to allow company to breakeven within a year of starting Percutaneous trial nearly finished with extension of label TRIPP study may allow extension of label to folfirinox Good team Enough cash if June 25 options exercised or underwritten Pengana on the register
Negatives FDA stalled
OSL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)